Aquila Capital Partners

Aquila Capital Partners is a venture capital firm based in New York, founded in the late 1990s by Mark E. Watson III. The firm focuses on backing innovative entrepreneurs who are developing transformational companies across various sectors, including fintech, insurance technology, artificial intelligence, biotechnology, and direct-to-consumer brands. Aquila Capital Partners provides both financial and intellectual capital, emphasizing a collaborative approach to business development. The firm aims to support ventures that have the potential to make a significant impact and shape the future.

Mark Watson

Co-Founder and Principal

3 past transactions

Xsphera Biosciences

Venture Round in 2023
Xsphera Biosciences focuses on oncology drug development and precision medicine through its innovative tumor preservation platform. This system is designed to create functional predictive assays that assess patient responses to cancer therapies. By capturing the entire tumor microenvironment, which includes immune cells, tumor cells, and stroma, Xsphera's technology allows for the storage of these components within multiple microfluidic channels. This capability enables drug developers to measure both the cytotoxic efficacy of treatments and the molecular responses, thereby enhancing the precision and effectiveness of oncology therapeutics.

NLX

Seed Round in 2022
NLX enables organizations to build and manage next generation conversational experiences - personalized conversations that are automated, integrated, measurable, highly scalable and available anytime and anywhere.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.